ruthenium has been researched along with 9-ethylguanine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caspers, SE; Haasnoot, JG; Hotze, AC; Kooijman, H; Reedijk, J; Spek, AL; van der Geer, EP | 1 |
| Garcìa, F; Haasnoot, JG; Kooijman, H; Reedijk, J; Spek, AL; van der Schilden, K | 1 |
| Corral, E; Hotze, AC; Magistrato, A; Reedijk, J | 1 |
| Amaresekera, T; Clarkson, GJ; Deeth, RJ; Hebden, AJ; McGowan, PC; Parsons, S; Sadler, PJ; van Rijt, SH | 1 |
| Cutillas, N; Espinosa, A; Hannon, MJ; Rodríguez, V; Ruiz, J | 1 |
| Balsano, E; Berger, W; Göschl, S; Hartinger, CG; Jakupec, MA; Jungwirth, U; Kandioller, W; Keppler, BK; Meier, SM; Roller, A | 1 |
| Bhattacharyya, S; Mukherjee, A; Purkait, K | 1 |
7 other study(ies) available for ruthenium and 9-ethylguanine
| Article | Year |
|---|---|
Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy
Topics: Crystallography, X-Ray; Drug Screening Assays, Antitumor; Guanine; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Organometallic Compounds; Ruthenium; Structure-Activity Relationship; Tumor Cells, Cultured | 2004 |
A highly flexible dinuclear ruthenium(II)-platinum(II) complex: crystal structure and binding to 9-ethylguanine.
Topics: Antineoplastic Agents; Binding Sites; Cations, Divalent; Crystallography, X-Ray; DNA; Guanine; Intercalating Agents; Organometallic Compounds; Platinum; Ruthenium | 2004 |
Interaction between the DNA model base 9-ethylguanine and a group of ruthenium polypyridyl complexes: kinetics and conformational temperature dependence.
Topics: Chemistry; Crystallography, X-Ray; DNA; Guanine; Kinetics; Magnetic Resonance Spectroscopy; Models, Chemical; Models, Molecular; Molecular Conformation; Pyridines; Ruthenium; Software; Temperature; Time Factors | 2007 |
Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
Topics: Adenine; Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Guanine; Humans; Hydrogen-Ion Concentration; Hydrolysis; Isomerism; Kinetics; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Organometallic Compounds; Osmium; Picolinic Acids; Quantum Theory; Ruthenium; Thermodynamics | 2009 |
A potent ruthenium(II) antitumor complex bearing a lipophilic levonorgestrel group.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Female; Guanine; Humans; Levonorgestrel; Models, Molecular; Ovarian Neoplasms; Ruthenium | 2011 |
Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity.
Topics: Amino Acids; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Coordination Complexes; Guanine; Humans; Naphthoquinones; Osmium; Reactive Oxygen Species; Rhodium; Ruthenium | 2013 |
Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cymenes; Drug Stability; Glutathione; Guanine; Humans; Hydrolysis; Ligands; Molecular Docking Simulation; Monoterpenes; Organometallic Compounds; Protein Conformation; Ruthenium; Vascular Endothelial Growth Factor Receptor-2 | 2017 |